PRUCALOPRIDE SUCCINATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PRUCALOPRIDE SUCCINATE (PRUCALOPRIDE SUCCINATE).
Selective serotonin 5-HT4 receptor agonist; enhances gastrointestinal motility by increasing acetylcholine release from enteric neurons.
| Metabolism | Primarily hepatic via CYP3A4; minor contributions from CYP2C8, CYP2D6, and CYP2C9. |
| Excretion | Primarily renal excretion (~60% unchanged drug) via active tubular secretion and glomerular filtration, with ~30% fecal as metabolites and unchanged drug. |
| Half-life | Terminal elimination half-life is approximately 26 hours (range 24–30 hours), allowing once-daily dosing. |
| Protein binding | Approximately 30% bound to plasma proteins (albumin). |
| Volume of Distribution | Vd is approximately 0.6 L/kg (range 0.4–0.8 L/kg), indicating distribution into total body water. |
| Bioavailability | Oral bioavailability is approximately 90% due to high absorption and minimal first-pass metabolism. |
| Onset of Action | Oral: Initial clinical effect (increased bowel movements) observed within 24–48 hours of first dose. |
| Duration of Action | Duration of action supports once-daily dosing; sustained improvement in bowel symptoms with continuous therapy. |
2 mg orally once daily.
| Dosage form | TABLET |
| Renal impairment | GFR 30-89 mL/min: No adjustment. GFR 15-29 mL/min: 1 mg once daily. GFR <15 mL/min or ESRD: Not recommended. |
| Liver impairment | Child-Pugh A or B: No adjustment. Child-Pugh C: Not recommended. |
| Pediatric use | Not approved for pediatric use. Safety and efficacy not established. |
| Geriatric use | No specific dose adjustment recommended; monitor for adverse effects due to potential age-related renal decline. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PRUCALOPRIDE SUCCINATE (PRUCALOPRIDE SUCCINATE).
| Breastfeeding | Prucalopride is excreted into human breast milk. The milk-to-plasma ratio (M/P) is approximately 0.4 after a single dose. The estimated daily infant dose is less than 0.1% of the maternal weight-adjusted dose. Based on this low excretion, breastfeeding is considered acceptable but caution is advised, especially in neonates or preterm infants. The manufacturer recommends discontinuing breastfeeding or the drug, taking into account the importance of the drug to the mother. |
| Teratogenic Risk | Prucalopride is classified as FDA Pregnancy Category C. In animal studies, no teratogenic effects were observed at doses up to 47 times the human therapeutic dose. However, there are no adequate and well-controlled studies in pregnant women. Limited human data do not suggest a major risk of malformations, but the drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Specifically, no increased risk of major birth defects has been reported; however, the possibility of fetal harm cannot be ruled out. |
■ FDA Black Box Warning
Not recommended for use in patients with a history of intestinal perforation or structural disorders of the GI tract.
| Serious Effects |
Hypersensitivity to prucalopride; intestinal perforation or obstruction; severe inflammatory conditions of the GI tract (e.g., Crohn's disease, ulcerative colitis).
| Precautions | Risk of intestinal perforation; avoid in patients with severe hepatic impairment; use caution in renal impairment. |
Loading safety data…
| Fetal Monitoring | No specific maternal-fetal monitoring is required beyond routine prenatal care. However, signs of maternal adverse effects such as headache, nausea, diarrhea, or abdominal pain should be monitored. For the fetus, standard ultrasound for growth and development is adequate. No specialized fetal monitoring is mandated. |
| Fertility Effects | In animal studies, prucalopride at high doses caused delayed sexual maturation and reduced fertility in female rats. However, no human studies have assessed fertility effects. Based on the mechanism (5-HT4 receptor agonist), there is no known direct impairment of human fertility, but caution is warranted in women of reproductive potential. It is not expected to adversely affect fertility at therapeutic doses. |